论文部分内容阅读
加替沙星于1999年获得美国FDA批准上市,2003年在中国上市,是喹诺酮类抗菌药的第四代新产品,其抗菌谱广,不但对于革兰氏阴性菌作用强,而且对于革兰氏阳性菌、非典型和厌氧菌感染的抗菌作用也等于和优于同类药
Gatifloxacin was approved by the US FDA in 1999 and listed in China in 2003. It is the fourth generation of quinolone antibacterial drugs with broad antimicrobial spectrum. It not only plays a strong role in Gram-negative bacteria, Antimicrobial effects of atypical and anaerobic infections are also equal to and better than those of similar drugs